Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604625 | 1.00 | LMNA (0.69) | LMNATP53MEN1KMT2A | |
| SCHEMBL6606316 | 0.87 | — | — | |
| SCHEMBL6606320 | 0.87 | — | — | |
| SCHEMBL8165384 | 0.87 | LMNA (0.64) | LMNATP53MEN1KMT2A | |
| SCHEMBL8165386 | 0.87 | LMNA (0.64) | LMNATP53MEN1KMT2A | |
| SCHEMBL6601294 | 0.84 | TP53 (0.62) | LMNATP53MEN1KMT2A | |
| SCHEMBL6601296 | 0.84 | TP53 (0.62) | LMNATP53MEN1KMT2A | |
| SCHEMBL6604095 | 0.83 | LMNA (0.58) | LMNATP53MEN1KMT2A | |
| SCHEMBL6604096 | 0.83 | LMNA (0.58) | LMNATP53MEN1KMT2A | |
| SCHEMBL6606056 | 0.82 | MEN1 (0.60) | TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | claimed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019113110-A2 | MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA | VANDERKLISH PETER (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-0968194-B1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6306864-B1 | CEREBRAL DEFICITS SUBSEQUENT TO OR RESULTING FROM CARDIAC BYPASS SURGERY AND GRAFTING, STROKE, CEREBRAL ISCHEMIA, SPINAL CORD TRAUMA, HEAD TRAUMA | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6303615-B1 | FOR THERAPY AND PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, CONVULSIONS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0901487-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997043276-A1 | NOVEL 2,3 DISUBSTITUTED-4(3H)-QUINAZOLINONES | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | LMNA 4525/4885TP53 4804/4885MEN1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.